Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TALWIN COMPOUND vs ANEXSIA 5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TALWIN COMPOUND contains pentazocine, a mixed agonist-antagonist at opioid receptors with partial agonist activity at mu receptors and full agonist activity at kappa receptors, and naloxone, an opioid antagonist that reduces abuse potential by precipitating withdrawal in opioid-dependent individuals when injected. The combination provides analgesia through pentazocine's central and peripheral opioid receptor activation, while naloxone is not absorbed orally but prevents intravenous abuse.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
1-2 tablets (each tablet contains pentazocine HCl 12.5 mg and aspirin 325 mg) orally every 3-4 hours as needed, not to exceed 6 tablets per day.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Pentazocine: 2-3 hours; naloxone: 1-1.5 hours. Clinical context: Repeated dosing may prolong effective half-life due to tissue accumulation.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; naloxone is metabolized primarily by glucuronidation in the liver.
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as conjugates.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Pentazocine: 60-70% bound to albumin and alpha-1-acid glycoprotein; naloxone: 40-50% bound to albumin.
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
Pentazocine: 4-5 L/kg (extensive tissue distribution); naloxone: 2-3 L/kg (rapid distribution to CNS).
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Oral: 20-30% (first-pass metabolism); IM/IV: 100%.
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
GFR 30-50 m L/min: administer every 4-6 hours; GFR 10-29 m L/min: administer every 6-8 hours; GFR <10 m L/min: not recommended due to aspirin component.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
Child-Pugh class B: reduce dose by 50% and extend interval to every 6 hours; Child-Pugh class C: avoid use due to risk of pentazocine accumulation and aspirin hepatotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
Not recommended for pediatric use due to aspirin risk of Reye's syndrome; pentazocine safety not established.
Not recommended for children under 18 years due to risk of respiratory depression.
Start with 1 tablet every 4-6 hours; monitor for CNS effects (dizziness, sedation) and GI bleeding; reduce dose if renal impairment present.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 3A4 INTERACTION. Addiction, Abuse, and Misuse: TALWIN COMPOUND exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Accidental Ingestion: Accidental ingestion of even one dose of TALWIN COMPOUND, especially by children, can result in a fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in withdrawal in the neonate, which may be life-threatening if not recognized and treated. Cytochrome P450 3A4 Interaction: The concomitant use of TALWIN COMPOUND with all cytochrome P450 3A4 inhibitors may result in an increase in pentazocine plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in pentazocine plasma concentration. Monitor patients receiving TALWIN COMPOUND and any CYP3A4 inhibitor or inducer.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Drug dependence,Increased intracranial pressure,Seizures in patients with seizure disorders,Abrupt discontinuation,Risks of driving and operating machinery
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to pentazocine, naloxone, or any component of the product
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
Avoid alcohol due to additive CNS depression and increased GI irritation. Take with food or milk to minimize aspirin-related gastric irritation. Avoid high-dose vitamin C (increases aspirin absorption). No other significant food interactions.
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
First trimester: Increased risk of neural tube defects due to aspirin component (pentazocine 12.5 mg + aspirin 325 mg). Second trimester: Risk of oligohydramnios and fetal renal impairment from aspirin. Third trimester: Premature closure of ductus arteriosus, persistent pulmonary hypertension, intrauterine growth restriction, and increased bleeding risk due to aspirin. Pentazocine may cause neonatal respiratory depression if used near term.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Pentazocine and aspirin are excreted into breast milk. M/P ratio not established. Aspirin may cause Reye's syndrome in infants, and pentazocine may cause drowsiness. Avoid breast-feeding due to risk of infant toxicity.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Generally contraindicated in pregnancy. If unavoidable, use lowest effective dose for shortest duration. No specific dose adjustment recommended due to lack of data; pharmacokinetic changes in pregnancy (e.g., increased clearance) may reduce efficacy, but risks outweigh benefits.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Talwin Compound contains pentazocine (opioid partial agonist) and aspirin (NSAID). Monitor for opioid-induced respiratory depression, especially in elderly or opioid-naive patients. Pentazocine may cause psychotomimetic effects (e.g., hallucinations, dysphoria) at higher doses. Avoid in patients with acute MI or those on MAOIs. Aspirin component increases bleeding risk; avoid with anticoagulants or history of peptic ulcer.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Take with food or milk to reduce stomach upset.,Do not crush or chew tablets; swallow whole.,Avoid alcohol while taking this medication.,May cause dizziness or drowsiness; do not drive until you know how it affects you.,Stop and seek medical help if you have signs of bleeding (e.g., black stools, vomiting blood) or allergic reaction (e.g., hives, difficulty breathing).,Use for short-term pain relief; long-term use may lead to dependence or kidney damage.,Store safely out of reach of children and dispose of unused medication properly.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TALWIN COMPOUND vs ANEXSIA 5/325, answered by our medical review team.
TALWIN COMPOUND is a Opioid Analgesic Combination that works by TALWIN COMPOUND contains pentazocine, a mixed agonist-antagonist at opioid receptors with partial agonist activity at mu receptors and full agonist activity at kappa receptors, and naloxone, an opioid antagonist that reduces abuse potential by precipitating withdrawal in opioid-dependent individuals when injected. The combination provides analgesia through pentazocine's central and peripheral opioid receptor activation, while naloxone is not absorbed orally but prevents intravenous abuse.. ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TALWIN COMPOUND and ANEXSIA 5/325 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TALWIN COMPOUND is: 1-2 tablets (each tablet contains pentazocine HCl 12.5 mg and aspirin 325 mg) orally every 3-4 hours as needed, not to exceed 6 tablets per day.. The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TALWIN COMPOUND and ANEXSIA 5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TALWIN COMPOUND is classified as Category C. First trimester: Increased risk of neural tube defects due to aspirin component (pentazocine 12.5 mg + aspirin 325 mg). Second trimester: Risk of oligohydramnios and fetal renal im. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.